Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

Benchmark  United States  NYSE  11,010   28.189 Index Moved Down -0.26%  

Collecting data for STEM

StemCells Inc

Year To Date
Last 1 Month(s)
Trading Day 
5 Days Price Trend
August 28, 2014 
Highest Price  
Lowest Price  
July 30, 2014 
August 19, 2014 

StemCells Market Sensitivity

As returns on market increase, returns on owning StemCells are expected to decrease at a much smaller rate. During bear market, StemCells is likely to outperform the market.
StemCells Inc Almost negative betaStemCells Inc Beta Legend
StemCells Inc
USA Stock
Benchmark NYSE
Contact Number: 510. 456. 4000
Currency: USD - US Dollar
Traded on Nasdaq Capital Markets
Current Valuation78.88 M
Shares Outstanding55.51 M
Number of Shares Shorted1.81 M
Revenue1.26 M
 United States SP 500   0.17 % Macroaxis: 0.17 Moved Down  
 United States Nasdaq   0.26 % Macroaxis: 0.26 Moved Down  
 United States NYSE   0.26 % Macroaxis: 0.26 Moved Down  
 United States Russel   0.58 % Macroaxis: 0.58 Moved Down  
 thisRed STEM STEM agains markets  2.22 % Macroaxis: change 2.22 Moved Down  
Compare to Competition   Compare Correlations

StemCells Leadership

Martin McGlynn CEO and President Director, Member of Strategic Transactions Committee, CEO of StemCells California Inc and President of StemCells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
Gregory Schiffman CFO, Executive Vice President - Finance, MBA
CPA MBA CFO and Executive VP of Fin.

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of StemCells to be traded at $1.4784 in 30 days

StemCells Price and Market Media

The median price of StemCells for the period between Tue, Jul 29, 2014 and Thu, Aug 28, 2014 is 1.61 with a coefficient of variation of 3.57. The daily time series for the period is distributed with a sample standard deviation of 0.06, arithmetic mean of 1.61, and mean deviation of 0.05. The Stock received some media coverage during the period.
StemCells Value
Change Benchmark  Embed  Timeline 

StemCells Summary

StemCells Inc [STEM] is traded on Nasdaq Capital Markets in USA. It is located in Newark, CA and employs 58 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 89.38 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 55.51 M outstanding shares of which 1.81 M shares are at this time shorted by private and institutional investors with about 3.5 trading days to cover.
StemCells, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for stem cellbased research and drug discovery and development. more
Over 30
Out Of

StemCells Alerts

StemCells Inc generates negative expected return over the last 30 days
StemCells Inc may become a speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 1.26 M. Net Loss for the year was (27.64 M) with profit before overhead, payroll, taxes, and interest of 886.64 K.
STEMCELLS INC currently holds about 26.46 M in cash with (23.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48.
Today Stocks StemCells Inc. Integrated Device Technology ...

StemCells Research Report

Generate Report  

StemCells Pair Trading Analysis

Correlation analysis and pair trading evaluation for StemCells and Gilead Sciences

Explore Investment Opportunities

Investing ideals could easily outperform a given market if properly optimized

StemCells Executives

CPA MBA CFO and Executive VP of Fin.

StemCells Directors

Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director
Ricardo Levy Independent Director
Alan Trounson Director

StemCells Management

Ann Tsukamoto Executive VP of Scientific and Strategic Alliances
George Koshy Chief Accounting Officer and Controller
Kenneth Stratton General Counsel

StemCells Fundamentals

Earnings Per Share vs Retained Earnings
Cash Flow from Operations vs Net Income
Earnings Per Share vs Current Valuation
Cash and Equivalents vs Net Income

StemCells vs Competition

StemCells vs. Gilead Sciences Inc
StemCells vs. Amgen Inc
StemCells vs. Biogen Idec Inc
StemCells vs. Celgene Corporation
StemCells vs. Regeneron Pharmaceuticals Inc
StemCells vs. Alexion Pharmaceuticals Inc
StemCells vs. Illumina Inc
StemCells vs. Vertex Pharmaceuticals Incorporated
StemCells vs. BioMarin Pharmaceutical Inc
StemCells vs. Jazz Pharmaceuticals Public Limited Company

StemCells August 28, 2014 Opportunity Range

Information Ratio(0.22)
Maximum Drawdown6.12
Value At Risk(3.59)
Potential Upside2.44

Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities